Sublingual apomorphine (APL‐130277) for the acute conversion of OFF to ON in Parkinson's disease

OFF episodes negatively impact quality of life in patients with Parkinson's disease (PD). There remains a need for an acute, effective, noninvasive treatment.

• Publication year

  2016

• Venue

  Movement Disorders

• Publication date

  2016-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/mds.26697PMID 27430123
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• acute conversion of off to on

  clinical endpoint

  A rapid switch from a Parkinson's disease OFF state to an ON state after treatment.

  Aliases: OFF to ON conversion

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewB (s683577b42) reviewq (76h6bfydm6) reviewAK (4715169a40) review
• noninvasive treatment

  treatment approach

  A treatment approach that does not require invasive procedures or implant-based delivery.

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewB (s683577b42) reviewq (76h6bfydm6) reviewAK (4715169a40) review
• off episodes

  clinical state

  Periods in Parkinson's disease when motor symptoms return or worsen and the patient is not in an optimal medication state.

  Aliases: OFF states

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewB (s683577b42) reviewq (76h6bfydm6) reviewAK (4715169a40) review
• parkinson's disease

  condition

  A neurodegenerative movement disorder mentioned as the patient population addressed by the treatment.

  Aliases: PD

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewB (s683577b42) reviewq (76h6bfydm6) reviewAK (4715169a40) review
• quality of life

  outcome

  A patient-centered outcome reflecting overall daily well-being and functioning.

  Aliases: QoL

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewB (s683577b42) reviewq (76h6bfydm6) reviewAK (4715169a40) review
• sublingual apomorphine

  treatment, drug formulation

  Apomorphine formulated for administration under the tongue as a treatment approach.

  Aliases: APL-130277

  박진우 (dztg5apj7m) extraction뀨 (7c402c1b98) reviewKiller Whale (322360f1c1) reviewmexicorea (qjvnbu8xg3) reviewB (s683577b42) reviewq (76h6bfydm6) reviewAK (4715169a40) review

• Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.

  2014cited by this paper
• Twenty Years of Apomorphine Therapy - How Does it Compare with Levodopa? Highlights of a Satellite Symposium Held at the 18th International Congress of Parkinson's Disease and Movement Disorders, Stockholm, 8-12 June 2014

  2014cited by this paper
• Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.

  2014cited by this paper
• Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's Disease*

  2011cited by this paper
• Open-Label Study Assessment of Safety and Adverse Effects of Subcutaneous Apomorphine Injections in Treating "Off" Episodes in Advanced Parkinson Disease

  2009cited by this paper
• Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.

  2008cited by this paper
• Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.

  2005cited by this paper
• Impact of the motor complications of Parkinson's disease on the quality of life

  2005cited by this paper
• Waiting for ON: A Major Problem in Patients With Parkinson Disease and ON/OFF Motor Fluctuations

  2003cited by this paper
• Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

  2001cited by this paper
• A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.

  2001cited by this paper
• Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study

  1997cited by this paper
• Pathogenesis of dyskinesias in parkinson's disease

  1989cited by this paper
• Oral bioavailability of apomorphine in the rat with a portacaval venous anastomosis.

  1980cited by this paper

• Motor and non-motor fluctuations in Parkinson’s disease: the knowns and unknowns of current therapeutic approaches

  2025cites this paper
• Current and emerging therapies for Parkinson’s disease: advances toward disease modification

  2025cites this paper
• Parkinson Disease Signaling Pathways, Molecular Mechanisms, and Potential Therapeutic Strategies: A Comprehensive Review

  2025cites this paper
• Bedarfsmedikation als Behandlung von Off-Phasen bei Parkinson-Patienten

  2025cites this paper
• Identification of the efficacy and safety of apomorphine in the treatment of Parkinson’s disease via meta-analysis

  2025cites this paper
• Levodopa inhalada: de la evidencia a la experiencia

  2024cites this paper
• Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease

  2024cites this paper
• Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson’s disease complicated by OFF episodes: a phase 3, open-label study

  2024cites this paper
• Dopamine agonists in the treatment of Parkinson's disease: the show must go on

  2024cites this paper
• Content CN-21-5

  2023cites this paper
• Management of OFF condition in Parkinson disease

  2023cites this paper
• Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study

  2023cites this paper
• Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson’s disease

  2023cites this paper
• Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson’s Disease

  2023cites this paper
• Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary?

  2023cites this paper
• Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions

  2023cites this paper
• Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes.

  2022cites this paper
• Intermittent Apomorphine Use for off Period Rescue in Parkinson's Disease: A Pragmatic Review of over Three Decades of Clinical Experience

  2022cites this paper
• Sublingual apomorphine in treatment of Parkinson’s disease: a review

  2022cites this paper
• Parkinson’s Disease - A Review on Advances and Treatment Strategies

  2021cites this paper
• Clinical Trials for Motor Complications in Parkinson’s Disease

  2021cites this paper
• Treatment of Parkinson’s Disease

  2021cites this paper
• On‐Demand Therapy for OFF Episodes in Parkinson's Disease

  2021cites this paper
• Apomorphine for the Treatment of Parkinson’s Disease

  2021cites this paper
• A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson’s disease

  2021cites this paper
• Non-Oral Drug Delivery in Parkinson's Disease: Current Applications and Future.

  2021cites this paper
• Emerging Pharmacotherapies for Motor Symptoms in Parkinson’s Disease

  2021cites this paper
• On demand therapy for Parkinson’s disease patients: Opportunities and choices

  2021cites this paper
• Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study

  2021cites this paper
• An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson’s disease

  2021cites this paper
• From OFF to ON—Treating OFF Episodes in Parkinson’s Disease

  2020cites this paper
• Management of Motor Features in Advanced Parkinson Disease.

  2020cites this paper
• Optimisation des traitements classiques et nouvelles perspectives thérapeutiques dans la maladie de Parkinson

  2020cites this paper
• Inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson’s disease

  2020cites this paper
• Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson's Disease.

  2020cites this paper
• Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson’s Disease

  2020cites this paper
• An evaluation of subcutaneous apomorphine for the treatment of Parkinson’s disease

  2020cites this paper
• Medical Management and Prevention of Motor Complications in Parkinson’s Disease

  2020cites this paper
• An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease

  2020cites this paper
• Therapeutic strategies for Parkinson’s disease: promising agents in early clinical development

  2020cites this paper
• Insomnia and Excessive Daytime Sleepiness in Parkinson’s Disease Patient—A Review Article

  2020cites this paper
• A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson’s disease ‘OFF’ episodes

  2020cites this paper
• Clinical Trials for in Parkinson’s

  2020cites this paper
• Pharmacotherapeutic Strategies to Treat or Prevent OFF Episodes in Adults with Parkinson's disease

  2020cites this paper
• The next chapter in symptomatic Parkinson disease treatments.

  2019cites this paper
• CVT-301 for Parkinson's disease: dose and effect size issues.

  2019cites this paper
• Progress of Pharmacological Approaches in Parkinson's Disease

  2019cites this paper
• Old Drugs, New Delivery Systems in Parkinson’s Disease

  2019cites this paper
• From medications to surgery: advances in the treatment of motor complications in Parkinson’s disease

  2019cites this paper
• CVT-301 for the treatment of Parkinson’s disease

  2019cites this paper
• Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.

  2019cites this paper
• Are All Dopamine Agonists Essentially the Same?

  2019cites this paper
• Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations

  2019cites this paper
• Parkinson disease

  2019cites this paper
• Medical and surgical management of advanced Parkinson's disease

  2018cites this paper
• Terapia pokročilých štádií Parkinsonovej choroby

  2018cites this paper
• Drug management in older Parkinson’s disease patients

  2018cites this paper
• Insights into the Molecular Mechanisms of Alzheimer’s and Parkinson’s Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology

  2018cites this paper
• Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson’s disease

  2018cites this paper
• Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date

  2018cites this paper
• Adjunctive Therapies in Parkinson’s Disease: How to Choose the Best Treatment Strategy Approach

  2018cites this paper
• Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features

  2018cites this paper
• Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.

  2018cites this paper
• Levodopa: A new look at an old friend

  2018cites this paper
• Update in therapeutic strategies for Parkinson's disease

  2018cites this paper
• Safinamide: an add-on treatment for managing Parkinson’s disease

  2018cites this paper
• Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.

  2017cites this paper
• Parkinson disease

  2017cites this paper
• New Symptomatic Treatments for the Management of Motor and Nonmotor Symptoms of Parkinson's Disease.

  2017cites this paper
• Disease Primers PARKINSON DISEASE

  2017cites this paper
• Motor Complications of Dopaminergic Medications in Parkinson's Disease

  2017cites this paper
• Update zur intensivierten Therapie des fortgeschrittenen idiopathischen Parkinson-Syndroms

  2017cites this paper
• Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease

  2017cites this paper
• Buccal mucosal irritation studies of sublingual apomorphine film (APL-130277) in Syrian golden hamsters.

  2016cites this paper
• Apomorphine therapy in Parkinson's and future directions.

  2016cites this paper
• Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future

  2016cites this paper
• Modern strategy and prospects in pharmacological treatment of Parkinson ’ s disease

  year unknowncites this paper
• NEUROLOGY AND PRECLINICAL

  year unknowncites this paper